Neurology · AntiepilepticRegulatory Approvalcompetitivenear-term

Lupin's Divalproex Sodium ANDA209286 Receives Abbreviated Approval

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Lupin Ltd.2 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/19/2026, 6:32:44 PM

Assessment confidence: 72% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Lupin's abbreviated approval for Divalproex Sodium signifies a new competitive entrant in the neurology market, which could disrupt pricing and market share dynamics. Portfolio teams must evaluate the implications of this approval on their strategies to maintain competitiveness. Regulatory context from FDA (FDA AP — DIVALPROEX SODIUM (SUPPL)) supports the near-term read. Assessment grounded in 20 ranked evidence items (11 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Lupin's entry on market share and pricing strategies for Divalproex Sodium. The strongest clinical anchor is Sodium Bicarbonate for the Treatment of Severe Metabolic Acidosis With Moderate or Severe Acute Kidney Injury in ICU (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Antiepileptic, 8 regulatory and 3 competitive items passed relevance filtering for Lupin.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DIVALPROEX SODIUM (SUPPL) (FDA). Entity match (lupin); Regulatory pathway relevance (nda). The approval has been granted under standard review, indicating no immediate regulatory concerns that would affect compliance or labeling.

Key Opportunities

The entry of Lupin could lead to increased competition, potentially affecting revenue and market share for existing players in the Divalproex Sodium market.
Portfolio teams should assess the impact of Lupin's entry on market share and pricing strategies for Divalproex Sodium.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and pricing strategies from Lupin and competitors.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (lupin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (lupin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAhigh relevance
Entity match (divalproex sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE (ORIG)
FDAhigh relevance
Entity match (lupin); Regulatory pathway relevance (nda)
FDA document
View source

Sodium Bicarbonate for the Treatment of Severe Metabolic Acidosis With Moderate or Severe Acute Kidney Injury in ICU
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and Mechanism of 'Yanjiu Needle' for Pharyngeal Dysphagia Based on sEMG Features
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Using randomization to compare AI and expert-generated formative assessment questions in medical education.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Lupin
Divalproex Sodium
existing generic competitors

Commercial impact

medium

The entry of Lupin could lead to increased competition, potentially affecting revenue and market share for existing players in the Divalproex Sodium market.

Regulatory impact

low

The approval has been granted under standard review, indicating no immediate regulatory concerns that would affect compliance or labeling.

What to watch

Monitor market entry timelines and pricing strategies from Lupin and competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.